The Role of CCL21/CCR7 Chemokine Axis in Breast Cancer Progression

Breast Cancer is a leading cause of cancer-related deaths worldwide, predominantly caused by metastasis. It is generally accepted that the pattern of breast Cancer metastasis is largely determined by the interaction between the chemokine receptors on Cancer cells and the chemokines expressed at the sites of metastatic disease. Chemokine receptors belong to the G-protein-coupled receptors (GPCRs) family that appear to be implicated in inflammatory diseases, tumor growth and metastasis. One of its members, C-C Chemokine Receptor 7 (CCR7), binds chemokines CCL19 and CCL21, which are important for tissue homeostasis, immune surveillance and tumorigenesis. These receptors have been shown to induce the pathobiology of breast Cancer due to their ability to induce cellular proliferation and migration upon the binding of the cognate chemokine receptors. The underlying signaling pathways and exact cellular interactions within this biological system are not fully understood and need further insights. Thus, in this review, we summarize the essential roles of CCR7 and its receptors in breast Cancer progression. Furthermore, we discuss the mechanisms of regulation that may lead to novel opportunities for therapeutic intervention. Despite the enormous advances in our knowledge of the nature of the chemokines in breast Cancer metastasis, research about the involvement of CCR7 in Cancer progression is still limited. Therefore, further studies are essential to illustrate the distinct roles of CCR7 in Cancer progression and validate its potential as a preventive bio-factor for human breast Cancer metastasis by targeting Chemokine Receptor genes.

CCL19; CCL21; CCR7; breast cancer; metastasis; signaling therapy.